Cargando…

Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia

Detalles Bibliográficos
Autores principales:	Ramdohr, Florian, Hennings, Robert, Monecke, Astrid, Kayser, Sabine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316243/ https://www.ncbi.nlm.nih.gov/pubmed/36546450 http://dx.doi.org/10.3324/haematol.2022.282282

Ejemplares similares

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
por: Garciaz, Sylvain, et al.
Publicado: (2022)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Yamamoto, Kazuhito, et al.
Publicado: (2021)

Correction to: Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
Publicado: (2023)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
por: Li, Zheng, et al.
Publicado: (2022)

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
por: Cherry, Evan M., et al.
Publicado: (2021)

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
por: Matthews, Andrew H., et al.
Publicado: (2022)

Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Xia, Leiming, et al.
Publicado: (2023)

Benefit of the Reduced Dose Combination of Azacitidine and Venetoclax in an Elderly Patient With Acute Myeloid Leukemia
por: Fujino, Keita, et al.
Publicado: (2023)

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
por: Pratz, Keith W., et al.
Publicado: (2022)

PB1862: VENETOCLAX AND AZACITIDINE THERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE RENAL IMPAIRMENT
por: Naka, Ryosuke, et al.
Publicado: (2023)

Atypical presentation of patients with chronic myeloid leukemia in chronic phase—Case report
por: Ramdohr, Florian, et al.
Publicado: (2022)

Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study
por: Jonas, Brian A., et al.
Publicado: (2022)

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
por: Pollyea, Daniel A., et al.
Publicado: (2022)

Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax
por: Ehsan, Hamid, et al.
Publicado: (2022)

Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine
por: Zhang, Alexander, et al.
Publicado: (2022)

A retrospective assessment of real-world experience with venetoclax and azacitidine therapy in elderly acute myeloid leukemia
por: Hu, Rong-Hua, et al.
Publicado: (2022)

PB1817: THE ADDITION OF ZALCITABINE TO ACUTE MYELOID LEUKEMIA TREATMENT MAY IMPROVE AZACITIDINE AND VENETOCLAX COMBINATION
por: Sofía, Álvarez-Galeano, et al.
Publicado: (2023)

Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations
por: Daido, Yusuke, et al.
Publicado: (2023)

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
por: Laloi, Louise, et al.
Publicado: (2022)

Sequential Combination of FLAM and Venetoclax plus Azacitidine to Bridge to Cord Blood Transplantation in a Patient with Primary Induction Failure Acute Myeloid Leukemia
por: Murakami, Hiroyuki, et al.
Publicado: (2022)

Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia
por: Cojocari, Dan, et al.
Publicado: (2021)

Venetoclax with Azacitidine Induced Tumor Lysis Syndrome in an Elderly Patient with Acute Myeloid Leukemia: A Case Report
por: Kim, Mihee, et al.
Publicado: (2021)

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
por: Konopleva, Marina, et al.
Publicado: (2022)

Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine
por: Ong, Shin Yeu, et al.
Publicado: (2022)

Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis
por: Guinan, Kimberly, et al.
Publicado: (2022)

Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens
por: Jensen, Christopher E., et al.
Publicado: (2022)

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
por: Gutman, Jonathan A., et al.
Publicado: (2023)

Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation
por: Zhao, Peng, et al.
Publicado: (2021)

Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States
por: Zeidan, Amer M., et al.
Publicado: (2023)

Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation
por: Teshima, Kazuaki, et al.
Publicado: (2023)

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Zeidan, Amer M, et al.
Publicado: (2023)

S310: VENETOCLAX PLUS AZACITIDINE DELAYS DETERIORATION OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: VIALE-A LONG-TERM FOLLOW UP
por: Pratz, Keith, et al.
Publicado: (2023)

Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States
por: Zeidan, Amer M., et al.
Publicado: (2023)

Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
por: Waclawiczek, Alexander, et al.
Publicado: (2023)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
por: Yuan, Linyu, et al.
Publicado: (2023)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19
por: Cristiano, Antonio, et al.
Publicado: (2022)

Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax + Azacitidine by Targeting Fatty Acid Desaturases 1 and 2
por: Culp-Hill, Rachel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nn5f0971kon8mbo2euds28gfm7